# A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma

Source: https://onco.cc/trials/nct07589257/  
OnCo record `nct07589257` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of VRT106 for injection in glioma & glioblastoma and diffuse midline glioma, H3 K27-altered, run by Guangzhou Virotech Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma is a phase 2 interventional study registered as NCT07589257 by Guangzhou Virotech Pharmaceutical Co., Ltd., with 10 participants planned, started 2026-05-07 and due to reach its primary completion in 2028-06-30. Interventions recorded: VRT106 for injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07589257
- Phase: 2
- Setting: A Single-Arm, Open-Label, Multicenter Phase II Clinical Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Including Diffuse Intrinsic Pontine Glioma
- Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd.
- Enrolled: 10

## Sources

- ClinicalTrials.gov NCT07589257: https://clinicaltrials.gov/study/NCT07589257

## Connected records

- cancers: [Diffuse midline glioma, H3 K27-altered (including DIPG)](https://onco.cc/cancers/dipg-dmg/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)

---
JSON: https://onco.cc/api/v1/entities/nct07589257.json